Adrenal gland – Strong INHA immunostaining in all cells of an adrenocortical adenoma.
Adrenal gland - Strong INHA immunostaining in all cells of an adrenocortical adenoma. Adrenal gland – Strong INHA immunostaining in an adrenocortical carcinoma. Immunostaining is reduced in an area of necrosis.
Adrenal gland - Strong INHA immunostaining in an adrenocortical carcinoma. Immunostaining is reduced in an area of necrosis. Adrenal gland – Strong INHA immunostaining in most cells of an adrenocortical adenoma. A fraction of cells do not stain, however (mosaic pattern).
Adrenal gland - Strong INHA immunostaining in most cells of an adrenocortical adenoma. A fraction of cells do not stain, however (mosaic pattern). Adrenal gland – Weak to moderate INHA immunostaining about 70% of the cells of an adrenocortical adenoma.
Adrenal gland - Weak to moderate INHA immunostaining about 70% of the cells of an adrenocortical adenoma. Breast – INHA negative invasive breast cancer of no special type (NST).
Breast - INHA negative invasive breast cancer of no special type (NST). Colon – Colorectal adenocarcinoma with focal weak to moderat INHA immunostaining (<5% of cells).
Colon - Colorectal adenocarcinoma with focal weak to moderat INHA immunostaining (<5% of cells). Esophagus – INHA negative esophageal squamous cell carcinoma.
Esophagus - INHA negative esophageal squamous cell carcinoma. Kidney – INHA negative clear cell renal cell carcinoma.
Kidney - INHA negative clear cell renal cell carcinoma. Kidney – Moderate to strong INHA immunostaining in a clear cell renal cell carcinoma.
Kidney - Moderate to strong INHA immunostaining in a clear cell renal cell carcinoma. Larynx – INHA negative squamous cell carcinoma.
Larynx - INHA negative squamous cell carcinoma. Liver – Moderate to strong INHA immunostaining in about 50% of the tumor cells of a cholangiocellular carcinoma.
Liver - Moderate to strong INHA immunostaining in about 50% of the tumor cells of a cholangiocellular carcinoma. Lung – Strong INHA positivity in an adenocarcinoma of the lung.
Lung - Strong INHA positivity in an adenocarcinoma of the lung. Ovary – INHA negative serous high-grade carcinoma. Scattered stroma cells show strong INHA positivity.
Ovary - INHA negative serous high-grade carcinoma. Scattered stroma cells show strong INHA positivity. Pancreas – INHA negative adenocarcinoma.
Pancreas - INHA negative adenocarcinoma. Pancreas – Moderate to strong INHA immunostaining in a pancreatic acinar cell carcinoma.
Pancreas - Moderate to strong INHA immunostaining in a pancreatic acinar cell carcinoma. Pancreas – Strong INHA immunostaining in the vast majority of the tumor cells of a neuroendocrine tumor.
Pancreas - Strong INHA immunostaining in the vast majority of the tumor cells of a neuroendocrine tumor. Penis – INHA positivity of variable intensity (mosaic pattern) in a penile squamous cell carcinoma.
Penis - INHA positivity of variable intensity (mosaic pattern) in a penile squamous cell carcinoma. Prostate – INHA negative prostatic adenocarcinoma (Gleason 3+3=6).
Prostate - INHA negative prostatic adenocarcinoma (Gleason 3+3=6). Skin – INHA negative Merkel cell carcinoma.
Skin - INHA negative Merkel cell carcinoma. Soft tissues – Granular cell tumor with strong INHA immunostaining.
Soft tissues - Granular cell tumor with strong INHA immunostaining. Stomach – INHA negative gastric adenocarcinoma.
Stomach - INHA negative gastric adenocarcinoma. Testis – INHA negative seminoma.
Testis - INHA negative seminoma. Thyroid – INHA negative papillary carcinoma.
Thyroid - INHA negative papillary carcinoma. Urinary bladder – INHA negative muscle-invasive urothelial carcinoma.
Urinary bladder - INHA negative muscle-invasive urothelial carcinoma. Urinary bladder – Muscle-invasive urothelial carcinoma with focal strong INHA immunostaining (<5% of cells).
Urinary bladder - Muscle-invasive urothelial carcinoma with focal strong INHA immunostaining (<5% of cells).